Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

... . "These two PR’s equal 3 separate labs looking at Brilacidin. Correct? .....

3/17/20 pr you note says, in part:

1. Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today further details on the Material Transfer Agreement (MTA) signed with a leading public health-focused U.S. university and top coronavirus expert.

2. This new research is independent of that being conducted on Brilacidin at one of the U.S. 12 Regional Biocontainment Labs (RBL). The RBL is testing Brilacidin’s potential inhibitory activity as a small molecule drug against SARS-CoV-2, the novel coronavirus responsible for COVID-19.

5/5/20 pr says, in part:

3. Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has executed a Material Transfer Agreement (MTA) with a leading U.S.-based Public Health Research Institute, with access to a Biosafety Level-3 (BSL-3) laboratory, to evaluate the immunomodulatory and antiviral properties of Brilacidin in relation to COVID-19. This new research is separate from the previously announced antiviral studies being conducted at a(not THE, my add) U.S. Regional Biocontainment Laboratory (RBL), which over the weekend informed us that the next phase of Brilacidin testing has commenced.

2 and 3 appear to be separate. Is/can #1 be affiliated with 2 or 3, or any of the three be affiliated? The pr's are very vague in terms of who s who. Boston University has RBL 4 rating. Would they then be cosidered capable of conducting RBL-3 level studies? IDK, I'll call HQ tomorrow and attempt to find out;).